It sits between tirzepatide (around 14.9% in SURMOUNT-1) and semaglutide (around 6.9% in STEP-1)
GLP-1 receptor agonism is the mechanism semaglutide uses alone
If you find that morning injection kills your appetite to the point where you cannot eat lunch or dinner on injection day, front-load your protein before injecting
Every other compounded GLP-1 provider I have ever seen or researched has a threshold set that looks something like this: To qualify for GLP-1s, you must have : 1.) BMI 30 (This qualifies as obese) OR 2.) BMI 27 plus at least one weight-related condition, such as: Type 2 diabetes High blood pressure High cholesterol Sleep apnea Insulin resistance or PCOS (depending on provider) Willow has put forth no such guidelines
As awareness grows, patients in Mumbai are increasingly asking: While Retatrutide is still progressing through regulatory pathways, understanding which patients may benefit from this advanced therapy can help individuals prepare for future treatment options
Koehler JA, Baggio LL, Lamont BJ, Ali S, and Drucker DJ
